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Abstract
Introduction Interleukin (IL)-22, originally referred to as
IL-TIF for IL-10-related T cell-derived inducible factor, is
a member of the IL-10-like cytokine family. IL-22 is
highly expressed by Th17 cells and is tightly linked to
chronic inflammation, including inflammatory bowel dis-
ease and local intestinal inflammation among others.
Materials and methods A PubMed and Web of Science
databases search was performed for studies providing
evidences on the role of IL-22 in liver diseases.
Conclusion IL-22 plays an important role in ameliorating
liver injury in many rodent models by targeting hepato-
cytes that express high levels of IL-22 receptor 1 and IL-10
receptor 2. This review concisely summarizes the role of
IL-22 in the development progression of liver disease of
different etiologies. It is focused mainly on the IL-22
intracellular signaling and its influence on liver diseases.
Keywords IL-22  Liver disease  Therapeutic
Introduction
Common liver disease represents an important cause of
mortality and morbidity. It is a rather dynamic process of
wound healing in response to a variety of persistent liver
injury caused by factors such as ethanol intake, chronic
hepatitis B virus (HBV) and hepatitis C virus (HCV)
infection, drugs, toxins, cholestasis, and metabolic disor-
ders [1]. Liver fibrogenesis is a common widespread
pathological damage and the initial results can be amplified
by an inflammatory response. Inflammatory responses upon
liver injury comprise resident as well as infiltrating
immune cells [2]. It is well known that innate immune cells
are important triggers of hepatic inflammation because the
liver is selectively enriched with macrophages (Kupffer
cells), natural killer (NK), and natural killer T (NKT) cells
[3].
Interleukin (IL)-22 is an IL-10 family cytokine member
produced primarily by T-helper (Th)17, Th22, and NK
cells [4, 5] (Table 1). IL-22 is highly expressed by IL-17-
producing cells, called Th17 cells [6, 7]. In addition to
Th17 cells, Th22 cells, a subset of CD4 ? T cells that
specifically express IL-22 and are mainly found in tissues,
produce IL-22 in response to IL-6 and tumor necrosis
factor-a (TNF-a), particularly in the skin [8]. IL-22 is also
produced by oligoclonal cdT cells that are detected in the
skin epidermis, gut, and lung epithelia [9]. NK cells pro-
duce IL-22 in response to IL-12 and IL-18 or IL-23 [10]. In
addition, retinoic acid-related orphan receptor gtpositive
(RORct?) innate lymphoid cells, including lymphoid tis-
sue inducer (LTi) and LTi-like cells, also express IL-22.
LTi-like cells express low constitutive levels of IL-22 that
are highly induced upon activation by IL-23 stimulation
[11].
IL-22 has been shown to be an important mediator in
dermal inflammation, and has protected mice from
inflammatory bowel disease (IBD) [12]. In patients with
IBD, diseases of the liver and the biliary tract are com-
monly observed. Moreover, drug-induced hepatotoxicity
and non-alcoholic fatty liver disease (NAFLD) are the most
frequent liver complications in IBD [13]. Therefore, IL-22
can provide protection to hepatocytes during liver
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inflammation. In this review, we summarize our current
understanding of the involvement of IL-22 in different
development and pathogenesis pathways of liver diseases,
as well as its clinical implications and therapeutic potential.
IL-22 and IL-22R and their biological functions
IL-22 is a member of the IL-10 cytokine family, initially
described in 2000 by Dumoutier et al. [14], and originally
referred to as IL-10-related T cell-derived inducible factor
(IL-TIF). The IL-10 family members share only a limited
primary sequence identity of about 13–25 %, but display a
common gene structure, a similar secondary protein
structure, and the use of the same receptor family. IL-22
shares 22 % amino acid sequence identity with IL-10 [15].
Human IL-22 protein is 146 amino acids in length and has
80.8 % identity with murine IL-22. Like other IL-10 family
members, the IL-22 structure contains six a-helices
(referred to as helices A to F) [16].
IL-22 exerts its biological activities through the inter-
action with a heterodimeric receptor complex composed of
IL-10 receptor 2 and the more restricted IL-22 receptor 1,
which is mainly expressed on intestinal and respiratory
epithelial cells, keratinocytes, and hepatocytes, but not on
cells of hematopoietic origin [17]. IL-22 binding to the IL-
22R complex induces a cascade of downstream signaling
pathways. The initial studies using a murine kidney cell
line demonstrated that IL-22R ligation activated the tran-
scription 3 (STAT3) pathway, and to a lesser extent,
STAT5 phosphorylation, while other studies reported that
IL-22R ligation activated the phosphorylation of STAT1,
STAT3, and STAT5 in a human kidney cell line. Using
the H4IIE rat hepatoma cell line, Lejeune et al. [18]
investigated that IL-22 signaling utilized c-Jun N-terminal
kinase (Jak1) and tyrosine kinase (Tyk2) to propagate
downstream phosphorylation signals, including mitogen-
activated protein kinase (MAPK) signaling pathways [p38
kinase, c-Jun N-terminal kinase (JNK), and extra cellular-
signal-regulated kinase 1/2 (ERK1/2), STAT1, STAT3,
and STAT5].
STAT3 signaling leads to the induction of genes
involved in many processes, including apoptosis, cell-cycle
progression, and angiogenesis. STAT3 is critical to proper
mouse development, and STAT3-deficient mice died early
in embryogenesis. Although liver-specific STAT3-deficient
mice had no abnormalities in liver development, they did
have a reduced ability to recover from liver damage [19].
Thus, activation of STAT3 and subsequent induction of a
variety of anti-apoptotic and proliferation-associated genes
seemed to contribute to the hepatoprotective and mitogenic
effect of IL-22 in the liver. The elevated IL-22 stimulated
STAT3 activation in hepatocytes and subsequently upreg-
ulated the expression of anti-apoptotic genes (e.g., B-cell
lymphoma-2 family, Bcl-2), anti-oxidative genes (e.g.,
metallothioneins 1 and 2), and mitochondrial DNA
repaired genes (e.g., 8-oxoguanine DNA glycosylase 1,
OGG1 and Nei-like homolog 1, Neil 1), and downregulated
the expression of lipogenic genes (e.g., sterol regulatory
element-binding proteins, SREBP-1c) [20]. Moreover,
blocking or deletion of STAT3 activation abolished the anti-
apoptotic and mitogenic actions of IL-22 in hepatic cells,
whereas the overexpression of a constitutively activated form
of STAT3 promoted hepatic stellate cell (HSCs) senescence
via p53- and p21-dependent pathways [21].
In view of the biological effects, IL-22 seems to be a
novel type of immune mediator. It does not affect immune
cells but regulates functions of certain tissue cells, although
it is produced by immune cells [17]. In summary, the
functions of IL-22 are (1) sustaining the integrity and
barrier functions of the tissues and (2) preventing damage
caused by either invading pathogens or the inflammatory
response itself [5, 22, 23]. In this process, IL-22 can
directly increase the innate immunity of tissue cells, protect
tissues from damage, and enhance their regeneration. IL-22
is a well-documented antioxidant factor for hepatocytes via
the upregulation of anti-oxidative genes (e.g., metallo-
thioneins 1 and 2) [24]. Finally, IL-22 treatment is a
potential adjunct therapy strategy for treating severe forms
of diseases because of its antiapoptotic, anti-steatotic,
antifungal [25], and antimicrobial effects, as well as the
potential added benefit of few side effects [24].
Table 1 The main cell source of IL-22
Cell type Location Transcription factor Stimulating cytokine References
Th1 (human) Blood Aryl hydrocarbon receptor (AHR) IL-12 [5]
Th17 Skin, intestine, lung Retoinic acid-related orphan receptor
(ROR) ct (mouse), RORC (human)
IL-6 [6]
Th22 Skin AHR IL-6, TNF-a [8]
cdT cells Skin, intestine, lung RORct (mouse) IL-1b1, IL-23 [9]
Natural killer T (NKT) cells Skin, intestine, lung Retoinic acid-related orphan receptor (ROR) IL-12, IL-18, IL-23 [10]
Lymphoid tissue inducer (LTi) cells Spleen Retinoic acid-related orphan nuclear hormone
receptor C (RORC)
IL-23 [11]
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IL-22 in the pathogenesis of liver disease
T cell-mediated hepatitis
Concanavalin A (Con A)-induced liver injury is a well-
established model of T-cell-mediated hepatitis [26]. Within
8–24 h, the administration of this mitogenic lectin resulted
in rapid liver inflammation and necrosis, and many features
of Con A injury were believed to resemble human auto-
immune liver disorders [27, 28]. Liver injury from large
doses of Con A was the result of a number of immune cell-
mediated and cytokine-driven responses and was depen-
dent upon activation of CD4 ? T cells, as the depletion of
these cells ameliorates hepatic injury [29]. It is reported
that after injection of Con A, IL-22 protein expression was
significantly increased, peaking between 1 and 9 h and
returning to basal levels at 24 h. IL-22 mRNA expression
was significantly increased by Con A injection in the intact
liver, hepatic mononuclear cells, and purified CD3 ? T
cells [30]. IL-22 blockade by neutralizing antibody or
genetic deletion markedly exacerbated liver injury in this
model [10], while the administration of recombinant IL-22
prevented Con A-induced liver injury. Injection of IL-22
rapidly induced STAT3 activation in the liver, and IL-22
blockade significantly reduced hepatic STAT3 activation in
T-cell-mediated hepatitis, indicating that IL-22 is also
partially responsible for hepatic STAT3 activation in this
model [20]. Activation of STAT3 subsequently led to the
upregulation of a variety of anti-apoptotic (e.g., Bcl-2, Bcl-
xL, Mcl-1) and mitogenic (e.g., c-myc, cyclin D1, Rb2,
CDK4) genes, which resulted in hepatoprotective effects
under conditions of liver injury. Moreover, IL-22-trans-
genic mice with an overexpression of IL-22 were
completely resistant to Con A-induced liver injury, while
IL-22-deficient mice were highly susceptible to such
injury.
Toxic liver injury
Carbon tetrachloride (CCl4)-induced liver fibrosis is a
well-established model in terms of its detrimental effects
for drug-induced liver injury and can be used in the clinic
to examine anti-hepatotoxic and/or hepatoprotective drugs
[1]. The Bin Gao groups revealed that overexpression of
IL-22 by either gene targeting (e.g., IL-22 transgenic mice)
or exogenous administration of adenovirus-expressing-IL-
22 (Ad-IL-22) could reduce liver fibrosis and accelerate the
resolution of CCl4-induced liver fibrosis during recovery.
Furthermore, IL-22 overexpression or treatment of IL-22
could increase the number of senescence-associated beta-
galactosidase-positive HSCs and decrease the expression of
alpha-smooth muscle actin in fibrotic livers in vivo and
in vitro. In vitro treatment with IL-22 induced the
activation of STAT3 in primary mouse and human HSCs.
Deletion of STAT3 prevented IL-22-induced HSCs
senescence in vitro, whereas the overexpression of a con-
stitutively activated form of STAT3 promoted HSC
senescence through p53- and p21-dependent pathways.
Finally, IL-22 treatment upregulated the suppressor of
cytokine signaling (SOCS) 3 expression in HSCs. Immu-
noprecipitation analyses revealed that SOCS3 bound to p53
and subsequently increased the expression of p53 and its
target genes, contributing to IL-22-mediated HSCs senes-
cence [31]. However, the study also declared that the IL-
22-mediated inhibition of liver fibrosis could not be com-
pletely mediated via its hepatoprotective effects because
IL-22 liver-specific transgenic (IL-22TG) mice displayed a
similar extent of liver injury after chronic CCl4-treatment
when compared with wild-type (WT) mice [31].
Acute liver injury induced by acetaminophen
or thioacetamide
Besides viral infections, acetaminophen (APAP, paraceta-
mol)-induced hepatotoxicity is a major cause of
hepatotoxicity and acute liver injury worldwide. Studies
showed that the therapeutic efficacy of recombinant IL-22
was assessed in the context of APAP-induced hepatotox-
icity. IL-22 application was associated with the
amelioration of histopathologic damage, reduction of
serum alanine aminotransferase activity, hepatic induction
of prototypic STAT3-inducible genes, and a tendency,
albeit not reaching significance in the set of experiments
performed, toward reduced mortality in otherwise fatal
intoxication. Because systemically applied IL-22 might not
be associated with acute immunomodulation/stimulation,
therapeutic activation of the IL-22-STAT3 axis may pro-
vide surplus therapeutic benefit for hard-to-treat patients,
for whom N-acetylcysteine frequently falls short.
In the thioacetamide-treated liver, IL-10 gene therapy
reversed hepatic fibrosis and prevented cell apoptosis.
Following gene transfer, the activation of a-smooth muscle
actin and cyclooxygenase-2 was significantly attenuated
[32]. However, the role of IL-22 in this model is unclear.
Alcoholic liver disease
Chronic alcohol drinking is a major cause of chronic liver
disease worldwide which results in a spectrum of liver
disorders that range from simple fatty liver to more severe
forms of liver injury such as alcoholic hepatitis, cirrhosis,
and hepatocellular carcinoma [33, 34]. Many mechanisms
underlying the pathogenesis of ALD including direct hep-
atotoxicity of ethanol and its metabolites, oxidative stress
generated by ethanol metabolism, activation of innate
immunity, elevation of pro-inflammatory cytokines and
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chemokines have been identified [35–38]. Regarding the
infiltration of leukocytes into inflamed liver tissue, T cells
have been described as a major part of the inflammatory
response following alcohol-induced liver injury, showing
high activity, for example by secreting a variety of
inflammatory cytokines such as IL-1b, IL-6, and TNF-a
in vitro after isolation [39–43]. Current therapeutic options
for alcoholic hepatitis include corticosteroids or TNF-a
inhibitor therapy; however, these treatments have gener-
ated controversial results and are associated with increased
rates of infection.
IL-22 treatment ameliorated steatosis and liver damage
in several models of liver injury, including chronic-binge
ethanol feeding, acute ethanol feeding, and high-fat diet-
induced fatty liver disease. Bataller R et al. [21] verified
that the hepatoprotective effect of IL-22 in alcoholic liver
injury was mediated the upregulation of anti-apoptotic
genes, anti-oxidative genes and the downregulation of
lipogenic genes in hepatocytes via the activation of STAT3
signaling pathway. Overexpression of IL-22 in vivo or
in vitro promoted liver regeneration or hepatocyte prolif-
eration, respectively. Additionally, IL-22 treatment may
potentially augment liver repair by promoting LPC prolif-
eration and survival. Therefore, co-treatment with IL-22
may diminish the side effect and prevent the inhibition of
liver regeneration because IL-22 has an antimicrobial
effect [44] and can promote liver regeneration [30, 45].
Furthermore, hepatic expression of IL-22R1 was upregu-
lated in patients with alcoholic hepatitis without elevation
of IL-22, suggesting that these patients may be sensitive to
IL-22 treatment.
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease is one of the most common
liver diseases in the Western world, with an estimated
prevalence of 17–33 %. It is reported that treatment with
oleic acid alone can induce a 4.8-fold increase of IL-22
mRNA compared to non-steatotic controls, and stimulation
with glycochenodeoxycholic acid (20 lmol/L) for 1 h can
induce a 10.7-fold increase of IL-22 mRNA compared to
unstimulated controls [46]. Studies showed that IL-22
administration reduced high-fat-diet (HFD)-induced ele-
vation of serum alanine aminotransferase and aspartate
aminotransferase (AST) levels, and partially inhibited
HFD-induced upregulation of lipogenesis-related genes
that are involved in lipid synthesis in the liver. Addition-
ally, IL-22 treatment prevented liver injury in mouse
models via the activation of STAT3, whose role in pro-
tecting against liver injury has been well documented.
Moreover, Yang et al. [47] recently reported that IL-22
treatment can ameliorate obesity-associated fatty liver by
downregulating several lipogenesis- and triglyceride
synthesis-related genes. Moreover, the activation of
STAT3 by recombinant murine IL-22 (rmIL-22) was
reduced by the overexpression of a dominant negative IL-
22R1 in this model. The levels of triglyceride and cho-
lesterol in the liver were significantly reduced by long-term
treatment of rmIL-22 in C57 black 6 (C57BL/6) and obese
(ob/ob) mice fed with HFD. The HFD-induced increases of
ALT and AST in ob/ob mice were ameliorated by rmIL-22
administration. In addition, the expression of fatty acid
synthase and TNF-a in the liver was decreased by long-
term rmIL-22 administration.
HBV hepatitis
Chronic hepatitis B is a complex heterogeneous disease
that progresses through different phases of immune toler-
ance (high HBV and low ALT), immune activity (high
HBV and high ALT), and immune inactivity (low HBV
and low ALT) [42]. Unlike chemically-induced liver
injury, the liver inflammation in the HBV-transgenic
mouse T-cell adoptive transfer model is potentiated by the
recruitment of inflammatory cells into the liver. This
recruitment requires specific cellular and protein mediators,
including neutrophils, chemokines, and matrix metallo-
proteinases, all of which can be induced by IL-22 [48].
Current studies demonstrated that CD3?T activated
NKT and NK cells, which were the major cell types that
produce IL-22 in the HBV-infected livers [49]. IL-22 may
play a proinflammatory role during acute HBV infection,
perhaps by amplifying immune cell infiltration and clear-
ance of virus, whereas it may play a more protective role
during chronic HBV infection [50]. In a model of HBV
replication in HBV transgenic mice, blocking IL-22 with a
neutralizing antibody ameliorated liver damage by reduc-
ing chemokine expression on hepatocytes, and
subsequently preventing hepatic recruitment of inflamma-
tory cells, suggesting that IL-22 may contribute to the
pathogenesis of HBV-mediated liver inflammation and
injury. In chronic Hepatitis B (HBV) infection, recent
reports indicated that IL-22 was an important factor that
regulates genes responsible for cell proliferation, survival,
and tissue repair, consistent with its protective roles in
certain contexts. Chronic HBV infection was associated
with the accumulation of IL-22-producing inflammatory
cells in the liver.
Although IL-22 has been reported to have no antiviral
activity against HBV replication, it appears to be a medi-
ator of the inflammatory response after recognition of HBV
by T cells in the liver and is a well-documented survival
factor for hepatocytes via the upregulation of anti-apoptotic
and antioxidant genes. Thus, in addition to the ability of IL-
22 to promote hepatocyte survival and proliferation, the
accumulation of IL-22-producing inflammatory cells may
522 C. Pan et al.
123
also play a critical role in liver stem cell (LPCs) prolifer-
ation via the activation of STAT3 in chronic HBV infection
[51]. IL-22 also increases the proinflammatory activity of
TNF-a, which is expressed in the liver after transfer of
HBV-specific T cells. Taken together, IL-22 may directly
or indirectly contribute to liver disease pathogenesis by
promoting the migration of inflammatory cells into the
liver, which can increase T cell-induced hepatocyte injury.
HCV Hepatitis
Infection with HCV is the major cause of chronic liver
disease, with an estimated global prevalence of 2.5 %,
which means 170 million people infected worldwide. The
serum levels of IL-22 in HCV were similar to the control
group. IL-22 mRNA expression is significantly higher in
HCV hepatitis than in cholestatic liver disease. However,
IL-22 did not directly regulate antiviral proteins and had no
effect on HCV replication, because IL-22 did not influence
the antiviral protein expression of MxA and 2’, 5’-oligoa-
denylates synthesis [52].
Dengue is a disease whose characteristics symptoms
include fever, back pain, retro-orbital pain, and rash, as
well as signs of liver involvement, usually detected by
slightly elevated aminotransferase levels [53]. DENV-2
infection led to a significant increase in the serum levels of
neutrophils, chemokine (C-X-C motif) ligand1 (CXCL1/
KC), interferon and chemokine (C–C motif) ligand5
(CCL5/RANTES) in the liver of infected mice. NK cells
(CD3-NK1.1 ?) were the main source of IL-22 in the liver
upon DENV-2 infection at day 6. Furthermore, liver sec-
tions of infected WT mice revealed signs of congestion,
haemorrhage, hepatocyte degeneration, and necrosis at day
6 p.i. However, there was more serious liver damage with
the deletion of IL-22 (IL-22-/-) upon DENV-2 infection,
with increased levels of transaminases in serum, greater
liver myeloperoxidase activity and exacerbated pathologi-
cal damage. The production of cytokine and chemokine
was also higher in the liver of infected IL-22-/- mice [54].
Hepatocellular carcinoma
Hepatocellular carcinoma is the fourth most common
malignancy worldwide with around 700,000 new cases
each year. In Edmondson Grade III–IV HCC patients,
serum IL-22 is significantly upregulated compared with
controls. IL-22 is excessively expressed in human HCC
tumor-infiltrated leukocytes (TILs) compared to peripheral
lymphocytes. IL-22 receptors are highly expressed in both
liver cancer and adjacent cirrhotic tissues compared to
normal controls. Enhanced tumor growth and metastasis
were found in mice that underwent subrenal transplantation
of MHCC-97H cells (hepatocellular cancer cells) co-
transplanted with IL-221 TILs. Jiang et al. [55] indicated
that in-vitro studies confirmed the effect of IL-22 on the
tumor-promoting and antiapoptotic cells, which is similar
to IL-6. In the HCC model, sustained and increased IL-22
expression and STAT3 activation were found in liver tis-
sues. Taken together, professors suggested that serum IL-
22 levels could be a negative prognostic indicator in
patients with HBV-related HCC, and that IL-22 should not
be used in patients with pre-cancerous cirrhosis or liver
cancer.
Liver ischemia-reperfusion injury and liver
transplantation
Liver ischemia–reperfusion injury (IRI) is a major com-
plication of hemorrhagic shock, liver resection, and
transplantation. A study presented by Paul et al. described
that significantly increased mRNA levels coding for IL-22
were detected at 24 h, and that the expression of IL-22R1
was increased by 6 h of reperfusion in mice that were
protected from IRI. Treatment of WT mice with recombi-
nant IL-22 markedly ameliorated serum aspartate
aminotransferase levels, moderated cardinal histological
features of IR damage (Suzuki’s score), and diminished
leukocyte sequestration, along with the expression of IL-
22R1 and pro-inflammatory cytokines. IL-22 antibody does
not appreciably affect IRI but increases IL-22R1 tran-
scription in the liver. Administration of IL-22 protein
exerts hepatoprotection by STAT3 activation. Treatment
with IL-22 protein may represent a novel therapeutic
strategy to prevent liver IRI in transplant recipients [56].
In a liver regeneration model, the levels of serum IL-22
protein and hepatic IL-22R1 mRNA expression are sig-
nificantly increased after 70 % partial hepatectomy.
Blockage of IL-22 with administration of an anti-IL-22
antibody before partial hepatectomy significantly
decreased hepatocytes proliferation [45].
Therapeutic implications of IL-22 in liver disease
Presently, increasing evidence in animal models and
humans have demonstrated the importance of IL-22 in the
initiation and maintenance of liver disease. IL-22 may have
promise as a potential therapeutic agent for liver diseases.
With the continued understanding of the molecular mech-
anisms of IL-22, together with knowledge on the capacity
of current drugs to target this pathological process, further
research may open an avenue to novel therapeutic options.
IL-22 administration ameliorated liver damage in almost
all models of liver injury. Overexpression of IL-22 in vivo
or in vitro promoted liver regeneration or hepatocyte pro-
liferation, respectively. IL-22 played dual roles in
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controlling liver inflammation: inhibiting liver inflamma-
tion by preventing hepatocyte damage, and subsequently
reducing necrosis-associated liver inflammation. Besides,
IL-22 treatment may potentially augment liver repair by
promoting LPC proliferation and survival in a STAT3-
dependent manner (Fig. 1). Finally, more importantly, IL-
22 therapy may have fewer side effects than conventional
therapy, due to the restricted expression of IL-22R1 on
epithelial cells (e.g., hepatocytes) and HSCs. All these
results indicated that IL-22 may be an more effective and
safer therapy for viral hepatitis and other liver diseases.
However, several points should be emphasized. First,
although IL-22 itself does not initiate liver tumor devel-
opment, IL-22 is able to promote existing liver cancer cell
proliferation and survival. Thus, it should not be used in
patients with pre-cancerous cirrhosis or liver cancer. Sec-
ond, IL-22 may play a proinflammatory role during acute
HBV infection, perhaps by amplifying immune cell infil-
tration and clearance of the virus, whereas it may play a
more protective role during chronic HBV infection.
Conclusions
Cytokines are attractive therapeutic targets in inflammatory
diseases because of their extracellular location and their
importance in regulating immune and inflammatory
responses. IL-22 has recently been considered to be another
important hepatoprotective cytokine because of its well-
documented hepatoprotective and antimicrobial functions,
as well as its potentially minimal adverse side effects.
Therefore, clinical trials examining combination therapy
with IL-22 for the treatment of patients with liver disease
are warranted.
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